Navigation Links
Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
Date:2/14/2008

SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report fourth quarter and year-end 2007 financial results on Wednesday, February 20, 2008, after the U.S. financial markets close.

Anadys will hold a conference call and webcast to discuss its fourth quarter and year-end 2007 financial results and the status of its development programs on Wednesday, February 20, 2008 at 5:00 p.m. Eastern Standard Time. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 63692537. The webcast and telephone replay will be available through March 5, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and the "Risk Factors" section of Anadys' Form 10-Q for the quarter ended September 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
3. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
6. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
9. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
10. Vion Pharmaceuticals Holds Special Meeting of Stockholders
11. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... OAKS, Calif. , Dec. 2, 2016 Amgen ... AGN ) today announced the submission of a Marketing ... ABP 215, a biosimilar candidate to Avastin ® (bevacizumab). ... application submitted to the EMA. "The submission ... as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ACEA Biosciences, Inc. ... Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, ... an update on the phase I/II clinical trials for AC0010 in patients with advanced ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... Computational Science Symposium (CSS) and the popularity of US Single Day Events (SDE) ... place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
Breaking Biology News(10 mins):